Pharmaceutical & Healthcare Annual Deals Analysis 2012GlobalDataFebruary 29, 2012 119 Pages - SKU: GBDT3806262 |
|
Hospital Construction in the US - Industry Market Research Report
5/3/2013 | published by: IBISWorld
Hospital Construction Over the next five years, the Hospital Construction industry is expected to enter into a recovery period. The implementation of the Patient Protection and Affordable Care Act will result in more than 32 million
|
read more...
|
$1,020.00
|
|
Business Strategy: Accountable Care Maturity Model
5/6/2013 | published by: IDC
This IDC Health Insights report discusses IDC Health Insights' Accountable Care Maturity Model. The relative immaturity of accountable care brings many challenges to the healthcare industry. IDC Health Insights' Accountable Care Maturity Model presents healthcare
|
read more...
|
$4,500.00
|
|
Perspective: mHealth in Canada — Smartphones and Apps Bring Better Healthcare to Your Fingertips
5/6/2013 | published by: IDC
This IDC Health Insights Perspective analyzes data from IDC Canada's ITAP n2 survey conducted in February 2013. The Web-based survey gathered input from healthcare providers across
|
read more...
|
$3,500.00
|
|
Switzerland Pharmaceuticals and Healthcare Report Q2 2013
5/8/2013 | published by: Business Monitor International
BMI View: While the patent cliff and the consequent availability of generic drugs, as well as price cuts ongeneric medicines and their increasing affordability, will work towards increasing the consumption ofgeneric medicines in Switzerland, BMI
|
read more...
|
$1,175.00
|
|
Australia Pharmaceuticals and Healthcare Report Q3 2013
5/8/2013 | published by: Business Monitor International
BMI View: As a developed market, Australia represents opportunities for risk averse pharmaceuticalinvestors, given its ageing and generally affluent population. Importantly, the government is implementingcost-cutting measures to cope with escalating healthcare costs, therefore generic drugmakers
|
read more...
|
$1,175.00
|
|
Cameroon Pharmaceuticals and Healthcare Report Q3 2013
5/8/2013 | published by: Business Monitor International
BMI View: Despite the strong growth potential of its pharmaceutical market, we believe Cameroon isunlikely to be of significant interest to multinational pharmaceutical firms. The country's shortcomingsinclude poor public health provision and rampant corruption. Consequently
|
read more...
|
$1,175.00
|
|
Namibia Pharmaceuticals and Healthcare Report Q3 2013
5/8/2013 | published by: Business Monitor International
BMI View: We expect Namibia's negative pharmaceutical trade balance to widen as demand for medicinescontinues to be met by imports, and poor local manufacturing sees exports contract in the medium term.Headline Expenditure Forecasts Pharmaceuticals: NAD2.20bn
|
read more...
|
$1,175.00
|
|
Nigeria Pharmaceuticals and Healthcare Report Q3 2013
5/8/2013 | published by: Business Monitor International
Executive Summary BMI View: Boosting bilateral co-operation between Nigerian buyers and Indian drugmakers will directlyobstruct the Nigerian government's goal to increase self-sufficiency in medicines production. We do notbelieve implementing a selected import ban on pharmaceuticals should
|
read more...
|
$1,175.00
|
|
Russian Pharma Industry In Details
5/9/2013 | published by: Euroresearch & Consulting
Russian Pharma Industry In Details
Purpose of this report was to analyze Russian of pharma.
Please pay attention:
Benefits of buying the report:
The report included large volume
|
read more...
|
$3,750.00
|
|
China Pharmaceutical Guidebook Series (4) 2013 Edition Material and Clinical Trial Requirements of Application and Approval for Imported Drug Registration: A Guidebook of Registration Application for Imported Traditional Chinese Medicines and Natural Medi
5/20/2013 | published by: Access China Management Consulting Ltd.
The traditional medicines in Orient, especially, the traditional Chinese medicines are always regarded by occidental as mysterious medicines. Until today not only the chemical composition of traditional Chinese medicines almost can not been expressed by
|
read more...
|
$750.00
|
Research assistance
We can help you find what you need. Call us or write us: Need help in your search?
US: 800.298.5699
Int'l: +1.240.747.3093
Related Markets
Prescription Drugs Reports